Costacurta is firmly committed to social and environmental responsibility, incorporating practices in its business model aimed at achieving these values.
The starry sky above me and the moral law within me.
Our main responsibility is to perform our work to the best of our ability, with the goal of creating employment and contribute – albeit proportionately to our size – to the economic growth of our country. Costacurta attributes great importance to the growth of the territory it operates in.
We firmly believe in the need to operate at the highest levels of correctness and compliance, fully observing applicable laws. Respecting the letter and spirit of the law is an essential prerequisite for Costacurta.
Costacurta pays particular attention to ethical standards in its business. Indeed, we believe that acting ethically is essential in achieving the goal of business continuity and long-term growth.
Over the years Costacurta has supported solidarity initiatives with the aim of creating a close relationship with the people who operate in the local community and the social services present there.
OUR CSR INITIATIVES
Since 2015, Costacurta S.p.A.-VICO has supported the Maria Letizia Verga Committee, a non-profit organization for the study and treatment of childhood leukaemia, with donations.
A long and inspiring journey that we will continue, TOGETHER.
What is the Maria Letizia Verga Committee
The Committee was created in 1979 by Giovanni Verga, naming it after his daughter Maria Letizia, who died from leukaemia at just 4 years of age.
Over the years, the Committee, based in Monza, has carried out a range of activities aimed at the study and treatment of childhood leukaemia, activities that have led to 2000 children being assisted and treated, working alongside doctors, researchers, paramedics and many volunteers who have collaborated with extraordinary passion and dedication.
The MRD project for childhood leukaemia
In 2019, Costacurta decided to support a specific project, funding the Minimum Residual Disease diagnostic test for children suffering from leukaemia.
Monitoring the Minimum Residual Disease (MRD) consists in measuring the number of leukaemia cells in children’s bone marrow after the first doses of chemotherapy, to better distribute the therapy, increasing it when the risk is greater and reducing it when it is less. Thanks to this clinical protocol, the survival rate has reached 85%, the quality of life has improved and the risks linked over the years to more aggressive therapies have been reduced.